Advertisement
|
|
|
|
|
Free Trial
Description: Malcolm Philips is CDex CEO/President. With a Lead411 subscription, CDex email addresses ( @cdex-inc.com ) of the executives are viewable. Other information includes Malcolm Philips email, phone, and extension.
Be sure to check our Linkedin tab on the company page. Typical management titles include VP, Chief, Vice President, Director, manager, & more. Similar names to Philips can be found at Executive Directory - Philips.
|
Add Malcolm Philips Information
Site Reference: http://www.cdex-inc.com/pages/pr_current.html#september23
Malcolm Philips CDEX CEO and Chairman. “We ended FY08 strong with an increase in the number of ValiMed units in the field, which not only increases sale and lease revenue, but also should contribute to a growing recurring revenue stream from service fees and the sale of supplies.” “Momentum is building,” added Pascal Pouligny, VP and GM of the Medication Safety Division at CDEX. “Leading hospitals have adopted our technology and ValiMed has been cited by key national patient safety associations and organizations. This activity has resulted in an increasing number of requests for information and demonstrations of our system, translating into sales and leases. Indeed, we are benefiting from greater industry awareness about and critical acceptance of our Medication Safety Products.” “Our future plans are exciting,” Pouligny continued. “First, we are introducing the next generation of ValiMed systems at the upcoming American Society of Health-System Pharmacists meeting in Orlando, Florida, CDEX CEO and Chairman. “Stephen is a well qualified financial executive with extensive and ongoing hands-on experience in public company filings that will enable him to build upon Augie DeLuca’s work of structuring financial systems that support our growing businesses. I would like to thank Augie for his invaluable service in guiding the financial group during a critical transition of our professional services to Tucson, Arizona. We wish the very best for him and his wife Carolyn as they will now have more time to travel and pursue other interests.” About CDEX Inc. CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets. The Valimed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line is a revolutionary new tool in the global battle against abuse of illegal drugs such as methamphetamine. CDEX and Pascal Pouligny, VP of its Medication Safety Division, met with European distributors to build upon the progress of its international expansion of ValiMed™. The CDEX delegation toured European hospitals in the United Kingdom, France and Spain, where interviews were held with hospital officials to discuss customized specifications for the Company’s medication safety products. Philips and Pouligny concluded that “our international expansion plans are moving forward on all fronts, with more details to follow in the coming weeks.” (For additional discussion see Mr. Philips’ CEO Corner on the Investor Page of the CDEX Web Site, www.cdexinc.com .) Philips and Pouligny met with business partner GRIFOLS International SA (BMAD: GRF) and senior managers at the Vall D’Hebron Hospital in Barcelona, Spain. GRIFOLS, a global provider of healthcare products and services, is the exclusive distributor of Valimed in Spain, Portugal and Italy. “Valimed is an ideal extension of the products and CDEX CEO. “While he will contribute in a number of areas within the Company, he will give us a much needed and experienced focus on investor relations. With the ramp up of our two product lines and the projection for FY2009 to be another year of significant revenue growth, keeping the investing public aware of progress becomes strategically important. We are honored that Dale has joined the CDEX Team to lead that effort.” About CDEX Inc. CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. Currently CDEX is organized to serve two strategic markets – Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID 2 Meth Scanner™ product line is a revolutionary new tool in the global battle CDEX CEO and Chairman. “We have expanded our customer base for ValiMed in the United States and continued to grow the distribution channel internationally. Significantly, we have expanded our ValiMed Medication Signature Library to include heparin, which as widely reported has been involved in several recent tragic incidents. In addition, we sold and shipped the first units of our new product line, the ID 2 Meth Scanner, and signed our first national and international Meth Scanner distributors. I should add that both the Meth Scanner and ValiMed product lines rely on the same patented technology, which gives the company leverage as we expand into new markets.” continued Mr. Philips. “With the launch of the Meth Scanner and the increasing market acceptance of ValiMed, we fully expect FY 2009 to be another year of record revenue, significantly surpassing FY 2008.” For more information on Mr. Philips’ assessment of the third Chief Executive Officer of CDEX, Inc. (OTCBB: CEXI) (www.cdex-inc.com) updated the investment community in an all-new interview with www.wallst.net. Topics covered in the interview include an overview of the company and its growth strategy, recent press releases, market opportunity, and upcoming milestones for investors to watch for. To hear the interview in its entirety, visit http://www.wallst.net , and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window. About WallSt.net www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. ( http://www.financialmediagroupinc.com ). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net , CEO of CDEX Inc., Discusses Recent Expansion of ValiMed™ and ID2 Meth Scanner™ Markets in an Exclusive Interview on WallSt.net's 3-Minute Press Show read collapse Monday July 21, 2008, 7 a.m. EST NEW YORK and TUCSON, ARIZONA, /PRNewswire-FirstCall/ — CDEX Inc. (OTCBB: CEXI), a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology, today announced that Malcolm Philips, the company's President and CEO, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show to discuss recent press releases related to its two product lines, ValiMed™ and the ID2 Meth Scanner ™. To view the clip in its entirety, visit: http://tv.wallst.net/3-minute-press/167/741/CEXI/malcolm-philips/cdex-inc . About CDEX Inc. CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique CDEX President and CEO. “We are very pleased that EURAF is joining the CDEX family. We look forward to developing a long and lasting relationship and working together to become a major player in the patient medication safety arena in France.” About CDEX Inc. CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. For more information, visit www.cdex-inc.com and www.valimed.com or contact Steve Schmidt ( sschmidt@cdex-inc.com ) or Pascal Pouligny ( ppouligny@cdex-inc.com ) (CEO), Tim Shriver (COO) and Steve Schmidt (VP and GM, Security Division) provided the briefing and responded to questions. Click here to listen to the recording of the teleconference. About CDEX Inc. CDEX, a technology development company currently developing and marketing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the ID2 Meth Scanner™ are CDEX solutions for the medication safety and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Steve Schmidt ( sschmidt@cdex-inc.com ) at 520.745.5172. Any Non-Historical statements are forward-looking, CDEX CEO. “Steve Winters and his Gemini Team have worked with us in fashioning an investment package that accomplishes these goals. We can now step up the pace of our strategic plans, including expansion of our product portfolio and distribution into global markets for both ValiMed and the Meth Scanner, acceleration of our R&D efforts for market entry of new product lines, and establishing a solid program of investor relations for our existing and new shareholders On July 8, 2008 at 11:00 a.m. EST, I will hold an open line teleconference to answer questions from investors regarding this financing package (monitor www.cdexinc.com ) for details.” The ValiMed™ Medication Validation System is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the ValiMed CDEX CEO. “I am extremely pleased to have senior executives heading these two divisions with a strong track record of successful sales and marketing. In addition I have appointed Dr. Wade Poteet as our CTO. Dr. Poteet has a distinguished career of developing breakthrough technologies and will focus his technology development on our two new divisions.” The ValiMed™ Medication Validation System is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the ValiMed database to detect significant medication and concentration errors as well as accidental and deliberate contamination, and provides the results in real time. The CDEX ID2 (Meth Scanner™) is a hand held, battery operated device that detects low nanogram range quantities of methamphetamine in a continuous scan mode from standoff ( mphilips@cdex-inc.com ) at 520.745.5172 X210. Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the Protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Sec. There is no obligation to publicly update any forward-looking collapse May 14, 2008 — CDEX INC Announces Partnership Cooperation with International Flagship Hospitals in Europe and the Middle East read collapse ValiMed™ Medication Validation System is currently installed at four major hospitals in Europe and the Middle East. Tucson, CDEX President and CEO. “We are honored that each of these flagship healthcare institutions has elected to partner with CDEX in testing the ValiMed system and establishing new standards and processes for patient medication safety.” About CDEX Inc. CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips ( mphilips@cdex-inc.com ) or Pascal Pouligny ( ppouligny@cdex-inc.com ) at 520.745.5172. ( mphilips@cdex-inc.com ) at 520.745.5172 X 210 or 207. Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements. collapse May 5, 2008 — General Robert H. “Doc” Foglesong, U.S. Air Force CDEX CEO and Chairman of the Board. “Leading organizations and bringing assets together to solve problems in national and international settings has been Doc Foglesong’s life work. That is also the CDEX vision as we assist in addressing major world problems such as medication errors, illegal drug use, explosive detection and distribution channels contaminated by counterfeit products. Doc Foglesong will be a major addition to the CDEX Team as we continue to move products into the mainstream national and international markets that assist with solving these problem. We are both pleased and honored that he has joined us in this work.” About CDEX Inc. CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs ( mphilips@cdex-inc.com ) at 520.745.5172 X 210 or 207. Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements. collapse April 14, 2008 — CDEX Announces Record Quarter in VALIMED™ Sales/Leases; CDEX will appear on The 3 Minute Press Show on www.WallSt.net on Monday, April 14, 2008 ( http://tv.wallst.net/3-min-press/3-min-press.php ) Tucson, Arizona – April 14, 2008 – CDEX Inc. (OTCBB: CEXI) announces record sales/leases of ValiMed™ units in its 2nd fiscal quarter ending April 30, 2008. “With the strong market demand and increasing number of hospitals in our customer pipeline both domestically and internationally, we have significantly increased the size of our current production run for ValiMed units,” said Tim Shriver, CDEX COO. “We have now ordered all of the major components for 115 Units, allocated for both the national and international markets.” The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and CDEX CEO. “We are tracking well to these goals. We expect to close the second quarter with ten new sales/leases of ValiMed units . CDEX revenues increased approximately 80% from 2006 to 2007, and we believe will substantially increase in 2008 based on our ValiMed product line alone, not including sales from our Meth Scanner™ which we expect to begin next quarter. We are pleased with this increasing number of ValiMed units in the field, which translates into an increasing recurring revenue stream, such as from sale of our patent pending cuvettes used with each ValiMed unit.” About CDEX Inc. CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); ( mphilips@cdex-inc.com ) or Cynthia Sampson ( csampson@cdex-inc.com ) at 520.745.5172 X 210 or 207. Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements. collapse April 9, 2008 — CDEX Inc CDEX President and CEO. “Patient Medication Safety is a global concern and a top priority in all hospitals. This announcement marks another concrete step in our goal of making ValiMed a safety standard worldwide.” About CDEX Inc. CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Pascal Pouligny ( ppoulignyt@cdex-inc.com ) at 520.745.5172 X 210. About GRIFOLS International SA. Grifols CDEX President and CEO. “Some of the finest hospitals and clinics in the US are currently participating in implementation of the healthcare system in the Middle East and this should facilitate the introduction of ValiMed into the region.” About CDEX Inc. CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips ( mphilips@cdex-inc.com ) or Pascal Pouligny ( ppoulignyt@cdex-inc.com ) at 520.745.5172 CDEX CEO. “We do not fully understand the long term health impacts of passive exposure to methamphetamine, such as from a home/apartment/hotel or used automobile where meth was used or made, or working in those locations. We do know that the immediate health impacts can be life threatening and long term impacts may result in cancer, as we have seen in numerous first hand reports and studies. In addition to assisting police forces, we believe that the Meth Scanner will provide a quick and low cost tool to identify hazardous locations before entry/purchase which will minimize overall risk to the public.” About CDEX, Inc. CDEX, a technology company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., ( mphilips@cdex-inc.com ) or Tim Shriver Jr. ( tshriverjr@cdex-inc.com ) 520.745.5172 X 201. Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements. collapse Recent Press Releases 2007 Press Releases 2006 Press Releases
|
|
| Copyright 2010 Lead411 | Santa Barbara, CA |
|
|
|
|
Advertisement
|
